A novel lipidomics-based approach to evaluating the risk of clinical hepatotoxicity potential of drugs in 3D human microtissues.
暂无分享,去创建一个
Wolfgang Moritz | Gabriele Cruciani | Jan Lichtenberg | Simone Sciabola | Laura Goracci | M. Aleo | L. Goracci | G. Cruciani | J. Lichtenberg | Simone Sciabola | A. Valeri | W. Moritz | Aurora Valeri | Michael D. Aleo | Aurora Valeri | Laura Goracci
[1] Kosuke Saito,et al. Evaluation of the Potential Risk of Drugs to Induce Hepatotoxicity in Human—Relationships between Hepatic Steatosis Observed in Non-Clinical Toxicity Study and Hepatotoxicity in Humans- , 2017, International journal of molecular sciences.
[2] Gabriele Cruciani,et al. Modeling Phospholipidosis Induction: Reliability and Warnings , 2013, J. Chem. Inf. Model..
[3] I. Zamora,et al. High-throughput, computer assisted, specific MetID. A revolution for drug discovery. , 2013, Drug discovery today. Technologies.
[4] Ze-jun Li,et al. Characterizing the mechanism of thiazolidinedione-induced hepatotoxicity: An in vitro model in mitochondria. , 2015, Toxicology and applied pharmacology.
[5] A. D. Rodrigues,et al. Inhibition of Hepatobiliary Transport Activity by the Antibacterial Agent Fusidic Acid: Insights into Factors Contributing to Conjugated Hyperbilirubinemia/Cholestasis. , 2016, Chemical research in toxicology.
[6] E. Nissinen,et al. Different toxicological profile of two COMT inhibitors in vivo: the role of uncoupling effects , 2002, Journal of Neural Transmission.
[7] L. Benet,et al. Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Subjects and Patients with Noninsulin‐Dependent Diabetes Mellitus , 1996, Journal of clinical pharmacology.
[8] L. Goracci,et al. A role for the autophagy regulator Transcription Factor EB in amiodarone-induced phospholipidosis. , 2015, Biochemical pharmacology.
[9] Reijo Laaksonen,et al. Lipidomics in drug discovery. , 2014, Drug discovery today.
[10] R. Beckmann. THE FATE OF BIGUANIDES IN MAN , 1968, Annals of the New York Academy of Sciences.
[11] J. Kelm,et al. Multi-cell type human liver microtissues for hepatotoxicity testing , 2012, Archives of Toxicology.
[12] J. Swinnen,et al. Lipidomics in drug development. , 2015, Drug discovery today. Technologies.
[13] S. Gaine,et al. Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension , 2009, European Respiratory Journal.
[14] B. Cocks,et al. Optimization of a single phase method for lipid extraction from milk. , 2016, Journal of chromatography. A.
[15] S. Krähenbühl,et al. Mechanisms of hepatocellular toxicity associated with dronedarone--a comparison to amiodarone. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.
[16] Weida Tong,et al. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. , 2016, Drug Discovery Today.
[17] T. Riise,et al. Quality of life as a predictor for change in disability in MS , 2000, Neurology.
[18] M. Aleo,et al. Liver safety evaluation of endothelin receptor antagonists using HepatoPac®: A single model impact assessment on hepatocellular health, function and bile acid disposition , 2019, Journal of applied toxicology : JAT.
[19] J. Kornhuber,et al. Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model. , 2008, Journal of medicinal chemistry.
[20] A. Leenhardt,et al. Amiodarone concentrations in plasma and fat tissue during chronic treatment and related toxicity. , 2009, British journal of clinical pharmacology.
[21] Volker M Lauschke,et al. Novel 3D Culture Systems for Studies of Human Liver Function and Assessments of the Hepatotoxicity of Drugs and Drug Candidates. , 2016, Chemical research in toxicology.
[22] Cynthia A Afshari,et al. A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.
[23] K. Ishak,et al. Amiodarone hepatotoxicity: Prevalence and clinicopathologic correlations among 104 patients , 1989, Hepatology.
[24] Simon Messner,et al. Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury , 2017, Archives of Toxicology.
[25] S. Klieber,et al. Identification of metabolic pathways and enzyme systems involved in the in vitro human hepatic metabolism of dronedarone, a potent new oral antiarrhythmic drug , 2014, Pharmacology research & perspectives.
[26] Lulu Chen,et al. Metformin and metabolic diseases: a focus on hepatic aspects , 2015, Frontiers of Medicine.
[27] Alex Avdeef,et al. Physicochemical Profiling (Solubility, Permeability and Charge State) , 2001 .
[28] L. Marroquin,et al. Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro. , 2008, Toxicology and applied pharmacology.
[29] R. McCallum,et al. Amiodarone-induced liver toxicity. , 1988, Annals of internal medicine.
[30] Hugh A Barton,et al. Setting Clinical Exposure Levels of Concern for Drug-Induced Liver Injury (DILI) Using Mechanistic in vitro Assays. , 2015, Toxicological sciences : an official journal of the Society of Toxicology.
[31] A. D. Rodrigues,et al. MOVING BEYOND BINARY PREDICTIONS OF HUMAN DRUG-INDUCED LIVER INJURY (DILI) TOWARDS CONTRASTING RELATIVE RISK POTENTIAL. , 2020, Chemical research in toxicology.
[32] A. Brunet,et al. Cross-Platform Comparison of Untargeted and Targeted Lipidomics Approaches on Aging Mouse Plasma , 2018, Scientific Reports.
[33] K. He,et al. Inhibition of MDR3 Activity in Human Hepatocytes by Drugs Associated with Liver Injury. , 2015, Chemical research in toxicology.
[34] L. Goracci,et al. Evaluating the risk of phospholipidosis using a new multidisciplinary pipeline approach. , 2015, European journal of medicinal chemistry.
[35] A. Sinclair,et al. The Evolution of Glucose-Lowering Drugs for Type 2 Diabetes , 2012 .
[36] Michelle M Wiest,et al. A lipidomic analysis of nonalcoholic fatty liver disease , 2007, Hepatology.
[37] K. Fujimori,et al. Very long-chain-fatty acids enhance adipogenesis through coregulation of Elovl3 and PPARγ in 3T3-L1 cells. , 2012, American journal of physiology. Endocrinology and metabolism.
[38] Samuel Kaski,et al. High Density Lipoprotein Structural Changes and Drug Response in Lipidomic Profiles following the Long-Term Fenofibrate Therapy in the FIELD Substudy , 2011, PloS one.
[39] Deborah I. Bunin,et al. Toxicogenomics and metabolomics of pentamethylchromanol (PMCol)-induced hepatotoxicity. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.
[40] K. Ekroos. Lipidomics: Technologies and Applications , 2012 .
[41] Macitentan: entry-into-humans study with a new endothelin receptor antagonist , 2011, European Journal of Clinical Pharmacology.
[42] Gabriele Cruciani,et al. LC/MS lipid profiling from human serum: a new method for global lipid extraction , 2014, Analytical and Bioanalytical Chemistry.
[43] Bernard Testa,et al. Drug Metabolism for the Perplexed Medicinal Chemist , 2009, Chemistry & biodiversity.
[44] L. Goracci,et al. Lipostar, a Comprehensive Platform-Neutral Cheminformatics Tool for Lipidomics. , 2017, Analytical chemistry.
[45] N. Ruderman,et al. The effects of troglitazone on AMPK in HepG2 cells. , 2017, Archives of biochemistry and biophysics.
[46] Milica Radisic,et al. Advances in organ-on-a-chip engineering , 2018, Nature Reviews Materials.
[47] Niroshini Nirmalan,et al. “Omics”-Informed Drug and Biomarker Discovery: Opportunities, Challenges and Future Perspectives , 2016, Proteomes.
[48] R. Krauss,et al. Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics Study , 2010, Metabolomics.